BRMS1L antibody (AA 151-246) (Cy5.5)
Quick Overview for BRMS1L antibody (AA 151-246) (Cy5.5) (ABIN730938)
Target
See all BRMS1L AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- AA 151-246
-
Cross-Reactivity
- Human
-
Predicted Reactivity
- Mouse,Rat
-
Purification
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human BRMS-1
-
Isotype
- IgG
-
-
-
-
Application Notes
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Expiry Date
- 12 months
-
-
- BRMS1L (Breast Cancer Metastasis-Suppressor 1-Like (BRMS1L))
-
Alternative Name
- BRMS-1
-
Background
-
Synonyms: Breast cancer metastasis-suppressor 1, BRMS1
Background: Transcriptional repressor. Down-regulates transcription activation by NF-kappa-B by promoting the deacetylation of RELA at 'Lys-310'. Promotes HDAC1 binding to promoter regions. Down-regulates expression of anti-apoptotic genes that are controlled by NF-kappa-B. Promotes apoptosis in cells that have inadequate adherence to a substrate, a process called anoikis, and may thereby inhibit metastasis. May be a mediator of metastasis suppression in breast carcinoma.
-
Gene ID
- 25855
-
UniProt
- Q9HCU9
Target
-